Verified employee & interview reviews

Syngene International Reviews

Bengaluru, Karnataka

—/ 5

0 reviews

Syngene International Limited is a leading global integrated contract research, development, and manufacturing organization (CRDMO) that offers end-to-end scientific solutions to the life sciences sector. Established in 1993 as a subsidiary of Biocon Limited, Syngene holds the distinction of being India's first Contract Research Organization (CRO). Over the decades, it has evolved from a pure-play research firm into an integrated service provider, delivering scientific services across the entire drug discovery, development, and commercial production lifecycle. Headquartered in Bengaluru, Karnataka, the company serves diverse sectors including pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals. The core operations of Syngene span across discovery, development, manufacturing services, and its unique Dedicated R&D Centers model. In the discovery phase, the company provides comprehensive services in synthetic and medicinal chemistry, biology, recombinant DNA engineering, cell line development, toxicology, and safety assessment. Its development vertical encompasses preclinical to clinical trials, covering chemical, analytical, formulation, and clinical development services to demonstrate drug safety and efficacy. On the manufacturing side, Syngene operates state-of-the-art, fully regulated, and current good manufacturing practice (cGMP) compliant facilities. These include a large-scale API manufacturing plant located at the Mangalore Special Economic Zone (MSEZ) and advanced biologics development infrastructure tailored for clinical and commercial supply. Syngene's innovative 'Dedicated Center' model involves building and operating long-term, exclusive R&D facilities tailored to the specifications of major global enterprises. The company maintains highly successful, long-standing strategic collaborations with pharmaceutical giants such as Bristol Myers Squibb (extended through 2035), Amgen, and Baxter, alongside research and manufacturing partnerships with organizations like GSK, Zoetis, and Merck KGaA. It supports an active client base of over 400 global organizations, including 13 of the top 15 global pharma companies, and jointly holds more than 400 patents with its clients. To sustain these wide-ranging operations, Syngene has established a vast infrastructure spanning over 2.5 million square feet of world-class R&D and manufacturing spaces across strategic campuses in Bengaluru, Hyderabad, and Mangalore. The company has also expanded its footprint internationally through its wholly owned US-based subsidiary, Syngene USA Inc. Its operations are powered by a robust workforce of over 8,500 employees, which includes a dedicated team of more than 5,600 highly skilled scientists. Financially, Syngene is a publicly traded entity listed on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) under the ticker SYNGENE. The company reported annual revenues exceeding 430 million USD. Led by Non-Executive Chairperson Kiran Mazumdar Shaw and Managing Director and CEO Peter Bains, the company operates with a strong corporate governance framework. Syngene emphasizes sustainability and environmental responsibility, achieving recognition as India's top pharma and biotech company for sustainability and being named among the World's Most Sustainable Companies by TIME Magazine and Statista.